Sofinnova

This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (October 2021)

This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (October 2020) (Learn how and when to remove this message)

Sofinnova is the name shared by two venture capital firms, Sofinnova Partners and Sofinnova Ventures. The name Sofinnova is a contraction of the French, "Société de Financement de l’Innovation" or, Innovation Venture Capital Company. Both firms trace their roots back to Sofinnova SA, an investment institution founded in Paris in 1972. The two firms have raised ~$4B since inception and have generally shared a similar investment strategy of financing projects and ideas in the life sciences and technology sectors. The firms distinguish themselves on the basis of their target geographies, stage of investment, and sectors. They have been independent entities since 1997.

• Sofinnova Partners is based in Paris, London, and Milan and focuses primarily on European biotech, medtech, biopharma, and industrial biotech investments, with a similar allocation for the US.
• Sofinnova Ventures has offices in Menlo Park, CA, and San Diego, CA, and focuses largely on US biotech investments, with ~20% allocation for Europe.

Sofinnova Partners and Sofinnova Ventures have historically shared some of the same Limited Partners, and have co-invested together in various life sciences companies including Flamel, Cerep, Genset, Actelion,^[1] Preglem, Movetis, Ascendis, Obseva, Auris and Nucana. The firms have a collegial relationship and exchange information and due diligence. The firms do not have an obligation to disclose deals or to co-invest, but historically have co-invested together in ~10% of their collective investments.